Ann M. Kapoun

Medicine · Health Sciences

38h-index6.4kcitations184works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(49), Colorectal Cancer Treatments and Studies(28), Lung Cancer Treatments and Mutations(22), Cancer Immunotherapy and Biomarkers(19), Pancreatic and Hepatic Oncology Research(18)

Publications184 total

Supplemental Tables 1-4 from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
2023Open Access
Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Supplemental Tables 1-4 from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
2023Open Access
Data from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
2023Open Access
Data from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Tables 1-5, Supplementary Methods and Materials from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Supplementary Table from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Data from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Supplementary Figure from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Data from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Data from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Table from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Supplementary Table from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Supplementary Table from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Supplemental Figures 1-4 from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
2023Open Access
Data from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Supplementary Figure from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Supplementary Table from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Supplementary Figures 1-5 from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Data from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Gilbert O’Young(14), Andrew A. Protter(11), Linda S. Higgins(11), Jakob Dupont(10), Robert Stagg(10), Lu Xu(10), Timothy Hoey(9), Marcus Fischer(8), Sarvajit Chakravarty(8), Satyanarayana Medicherla(8), Austin Gurney(7), Jennifer Cain(7), John Lewicki(7), George F. Schreiner(7), Ying Jing(7), Sundeep Dugar(7), Wan-Ching Yen(6), Andrew Lam(6), Rashmi Chugh(6), Rainer K. Brachmann(6)